Renal Cell Carcinoma
Systemic therapy for mRCC: second line and beyond
Educational Objective: Recognise the optimal treatment strategy for patients with advanced renal cell carcinoma (RCC) progressing after previous therapy.
Specialty: Medical oncology
Target Audience: Specialists (CME: basic, intermediate), Residents (senior)
Latest update: January 2024
Background:
Regulatory approval status of drugs for the treatment of advanced/metastatic RCC, mentioned in the CME courses on first- and later-line management (status 10 January 2024)
This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.